

- When patients with type 2 diabetes do not achieve glycemic control with basal insulin, the intensification options that have been available until recently can improve glycemic control but may also increase rates of hypoglycemia and weight gain.
- This study estimated the effects of four intensification strategies in such patients: use of the combination product insulin degludec/liraglutide (IDegLira); addition of liraglutide to basal insulin ('glucagon-like peptide-1 receptor agonist add-on strategy'); basal-bolus insulin; or up-titration of basal insulin.
- Based on an indirect comparison, estimated reductions in HbA<sub>1c</sub> were greater with IDegLira versus the other options, and estimated changes in body weight and rates of hypoglycemia favored IDegLira versus basal-bolus insulin or up-titration of basal insulin.
- Our data suggest that IDegLira is more effective, with lower hypoglycemia rates and less weight gain, than up-titrated basal insulin or basal-bolus insulin in patients uncontrolled on basal insulin.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Novo Nordisk. Medical writing assistance for this study was provided by Grace Townshend and Daria Renshaw (Watermeadow Medical). For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).